Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cells
Stem Cells Embryonic New – Video
Posted: November 18, 2012 at 11:44 am
Stem Cells Embryonic New
From:ObandoAPBandHBViews:1 0ratingsTime:02:02More inEducation
See the rest here:
Stem Cells Embryonic New - Video
Posted in Stem Cells
Comments Off on Stem Cells Embryonic New – Video
LAMININE – Video
Posted: November 18, 2012 at 11:44 am
LAMININE
Specification of Laminine - Fibroblast Growth Factor - 2 LAMININE - A Functional Superfood For The 21st Century Nature #39;s perfect food has long been considered to be the lowly egg. The biological value of its protein is second only to mother #39;s milk for its ability to promote cell growth, repair and regeneration. Yet, the secret power of the egg, is only beginning to be understood. One man, ahead of his time, discovered the potent adaptogenic effect contained within a bio-rich extract taken from a fertilized egg on the ninth day of development. Taken at the peak of the first developmental phase, just before the differentiation of cells, this special extract nourishes the body with such a pure source of nutrition and "life force" that it acts as an adaptogen promoting homeostasis throughout the body. The results can be remarkable. What is Laminine? Laminine is a complete Synergy of : 22 Amino Acids Trace Minerals Vitamins Fibroblast Growth Factor (FGF) Laminine contains a patented bio-rich extract from fertilized eggs that acts as a powerful "adaptogen". To this base ingredient additional amino acids from plant and marine sources are added to create a complete amino acid profile. The proprietary formula contains 22 amino acids, trace minerals and vitamins. It is also the only known food source of Fibroblast Growth Factor-2 (abundant before birth) which is thought to mobilize and instruct the body #39;s stem cells to do their repair work. It is believed that these instructions ...From:GILBERT SANTOSViews:14 0ratingsTime:08:04More inScience Technology
Continued here:
LAMININE - Video
Posted in Stem Cells
Comments Off on LAMININE – Video
Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells – Video
Posted: November 18, 2012 at 11:44 am
Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells
David Larocca. Advanced Cell Technology Inc., Burnham Institute for Medical Research, La Jolla, CA Pluripotent stem cells whether from embryonic (ES) or induced (iPS) cells offer a potentially unlimited source of replacement cells for treating human degenerative diseases associated with aging such as cardiovascular disease, macular degeneration, aging skin, diabetes, Parkinson #39;s, and Alzheimer #39;s disease. The availability of iPS cells will no doubt increase the number of research grade ES-like cell lines dramatically and may ultimately fulfill the need for patient specific stem cells. However, a significant problem and potential bottleneck to developing stem cell therapies is the development of efficient tools and technologies for directed differentiation of pluripotent stem cells toward therapeutic cell types. Currently, this process is poorly understood and often yields differentiated cells that represent only a few percent of the starting ES cells which are difficult to scale up. Identification of surface markers of lineage specific progenitor cells would provide tools for tracking, isolating and scaling these cells to improve differentiation yields and increase our understanding of ES cell differentiation in vitro. Toward this end, we have isolated progenitor cell-targeting peptides by selecting phage display libraries on differentiating ES cells. We have used the cell-targeting peptides or peptide phage themselves to target fluorescent nanoparticles (quantum dots) to ...From:Jeriaska JeriaskaViews:0 0ratingsTime:17:08More inEducation
See the rest here:
Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells - Video
Posted in Stem Cells
Comments Off on Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells – Video
Dr. Keith Tansey at the Spinal Cord Workshop 2012 – Video
Posted: November 18, 2012 at 11:44 am
Dr. Keith Tansey at the Spinal Cord Workshop 2012
Keith Tansey, MD, PhD Director, Spinal Cord Injury Research, Shepherd Center Talk title: Stem Cells in Spinal Cord Injury: a Medical Physiologists ViewFrom:bedfordstemcellViews:1 0ratingsTime:01:02:24More inScience Technology
Original post:
Dr. Keith Tansey at the Spinal Cord Workshop 2012 - Video
Posted in Stem Cells
Comments Off on Dr. Keith Tansey at the Spinal Cord Workshop 2012 – Video
Stem Cells explained by Dr Newman – Video
Posted: November 18, 2012 at 11:44 am
Stem Cells explained by Dr Newman
Stem Cell technology based on 200+ growth factors that supports the DNA, replenishes the skins natural levels of proteins like collagen elastin, reconstructing the aging process by repairing and regenerating the skin cells. Introducing "Luminesce"- giving you age defying radiance and luminosity. http://www.cellrenewals.jeunesseglobal.comFrom:CellrenewalsViews:0 0ratingsTime:02:16More inScience Technology
Follow this link:
Stem Cells explained by Dr Newman - Video
Posted in Stem Cells
Comments Off on Stem Cells explained by Dr Newman – Video
2012-11.17-Ask the Experts- “Living with ALS” – Video
Posted: November 18, 2012 at 11:44 am
2012-11.17-Ask the Experts- "Living with ALS"
Tune in LIVE on Saturday, November 17 from 3-6 pm Viewers can ask the experts their questions via the "Live Chat" feature or you can send an email to asktheexperts@alsagoldenwest.org Program Schedule: 3:00 pm- Important Aspects in Clinical Care Multidisciplinary Care and ALS Catherine Lomen-Hoerth, MD, PhD Director, The ALS Center at UCSF Communicating with ALS Ilyssa Abaranok, MS CCC-SLP AAC Specialist, The ALS Association Golden West Chapter Meeting Your Mobility Needs David Beals, ATP Brett Zaer, ATP Superior Mobility 5:00 pm - Research Developments Overview of ALS Research Lucie Bruijn, PhD Chief Scientist, The ALS Association Genetics of ALS Robert H Baloh, MD, PhD Director, Cedars-Sinai ALS Center Novel Approaches, Therapies, and Genes Don W. Cleveland, PhD Departmental Chair of Cellular and Molecular Medicine University of California, San Diego Stem Cells and ALS Clive Svendsen, PhD Director, Cedars-Sinai RMIFrom:alsagoldenwestViews:131 0ratingsTime:02:12:48More inNonprofits Activism
View post:
2012-11.17-Ask the Experts- "Living with ALS" - Video
Posted in Stem Cells
Comments Off on 2012-11.17-Ask the Experts- “Living with ALS” – Video
BODY of Santa Fe Unveils the BODY Natural Facelift: Innovative Facial Mimics the Effect of a Facelift Using Stem Cell …
Posted: November 18, 2012 at 11:44 am
This custom made, cutting edge spa treatment at the BODY Spa at BODY of Santa Fe allows clients to experience the tightening effects of a facelift without the expense or intrusion of surgery. Using technologies such as cryogenic stem cells, ultrasonic, LED light and
Santa Fe, NM (PRWEB) November 15, 2012
After a careful skin analysis, the BODY Natural Facelift begins with a deep cleansing, utilizing either microdermabrasion or a 100% organic herbal enzyme peel, followed by the application of ECOCERT certified Plant Stem Cells (Naturopathica products) or Cryogenic stem cells developed by the DNA Health Institute utilizing pure bovine origin stem cells (from the first trimester embryonic fluid of organic grass fed cows in France)*. The cells been proven to slow cellular aging and counteract a variety of skin problems leaving skin more hydrated, better nourished, less aged, and more radiant. The Natural Facelift treatment is applied with either the plant based products from Naturopathica or DNA Health Institute products.
BODY of Santa Fes highly trained therapists then custom design a blend of cutting edge, non-invasive therapies to amplify collagen and microcurrent to tighten skin and firm and tone facial muscles. LED light is then used to stimulate collagen and correct skin damage followed by ultrasonic therapy to deeply hydrate. Skin is left glowing and healthy with noticeable results after only one treatment.
I created the BODY Natural Face Lift to give our clients an alternative to plastic surgery, said BODY owner Lorin Parrish. As time passes, every cell loses strength and becomes more independent as its surrounding tissue deteriorates and runs slower and rougher. Cells need other cells for information, support, nourishment and direction; for skin to work the way it does, every cell must work in perfect unison with its surrounding tissue.
The BODY Natural Facelift is appropriate for all skin types and skin tones and is available for body treatment areas including the derriere, thighs, stomach, underarms, and chest. The BODY Natural Facelift is $175 for a 90-minute session and a series of 10 sessions is available for $1495. For more information about the Natural Facelift or to make spa reservations, please visit http://www.bodyofsantafe.com or call (505) 986-0362.
*The humane process of extracting bovine embryonic fluidrich in nutrients and stem cellshappens during carefully calculated specific timeline (within the first trimester of the bovines pregnancy) to achieve maximum amounts of stem cells, which have not become specific to the bovine composition, but contain the DNA information to influence and support human skin.
For press inquiries, contact:
Jennifer Hinsley
JLH Media
Posted in Stem Cells
Comments Off on BODY of Santa Fe Unveils the BODY Natural Facelift: Innovative Facial Mimics the Effect of a Facelift Using Stem Cell …
BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial
Posted: November 18, 2012 at 8:00 am
The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.
Kevin McCormack, senior director for
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
Responding to a question from the
California Stem Cell Report, McCormack said,
California Stem Cell Report, McCormack said,
“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”
McCormack later added that BioTime
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
The stem cell agency made its $25
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
The company has tried to sell the
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
News from clinical trial is expected to
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
Geron's stock traded at $1.24 at the
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial
Geron, BioTime Deal Moves Forward with Letter of Intent
Posted: November 18, 2012 at 8:00 am
Geron Corp., which once pioneered human
embryonic stem cell research, is close to selling off its hESC business in a complicated deal involving two former CEOs of the company and
BioTime, Inc., of Alameda, Ca.
The two publicly traded firms yesterday
announced a “letter of intent” involving a transaction in which
BioTime would acquire the assets of Geron's hESC clinical trial that
the company suddenly abandoned last year. The firm also laid off 66 people,
about 40 percent of its staff.
announced a “letter of intent” involving a transaction in which
BioTime would acquire the assets of Geron's hESC clinical trial that
the company suddenly abandoned last year. The firm also laid off 66 people,
about 40 percent of its staff.
Abandonment of the program came only a
few months after the $3 billion California stem cell agency loaned Geron $25 million to assist in the trial. The agency could
restore the loan for the trial, but the Geron-BioTime announcement
did not mention that possibility. The California Stem Cell Report has
asked the agency for comment.
few months after the $3 billion California stem cell agency loaned Geron $25 million to assist in the trial. The agency could
restore the loan for the trial, but the Geron-BioTime announcement
did not mention that possibility. The California Stem Cell Report has
asked the agency for comment.
The letter of intent came one year and
one day after Geron announced that it was giving up the hESC spinal injury trial because of financial reasons. The Menlo Park, Ca., firm
has been trying to sell its hESC assets since then. BioTime has
been the only firm to express public interest. The Geron trial was
the first hESC trial approved by the FDA.
one day after Geron announced that it was giving up the hESC spinal injury trial because of financial reasons. The Menlo Park, Ca., firm
has been trying to sell its hESC assets since then. BioTime has
been the only firm to express public interest. The Geron trial was
the first hESC trial approved by the FDA.
The proposed deal involves Michael
West, who founded Geron and is now head of Biotime, and Tom Okarma,
who was CEO of Geron from 1999 to 2011. Okarma is now head of BioTime
Acquisition Corp.,(BAC) a subsidiary of BioTime.
West, who founded Geron and is now head of Biotime, and Tom Okarma,
who was CEO of Geron from 1999 to 2011. Okarma is now head of BioTime
Acquisition Corp.,(BAC) a subsidiary of BioTime.
Also involved is an unnamed private investor who would provide $10 million.
Here is how yesterday's press release
described the deal in which BioTime would acquire Geron's
“intellectual property and other assets related to Geron’s
discontinued human embryonic stem cell programs.”
described the deal in which BioTime would acquire Geron's
“intellectual property and other assets related to Geron’s
discontinued human embryonic stem cell programs.”
“ BioTime would contribute
to BAC $5 million in cash, $30 million of BioTime common
shares, warrants to purchase eight (8) million common shares
of BioTime at a pre-specified price, rights to use certain
human embryonic stem cell lines, and minority stakes in two of
BioTime’s subsidiaries. In addition, a private investor would
invest $5 million in cash in BAC.
“Following consummation of the
potential transaction, Geron stockholders would receive
shares representing 21.4% of the common stock of BAC as well as
warrants to purchase 8 million shares of BioTime common
stock at a pre-specified price. BioTime would own
approximately 71.6%, and a private investor would own approximately
7.0% of the outstanding BAC common stock for their $5
million investment. BioTime would also receive
warrants that would enable it to increase its ownership in BAC by
approximately 2%, which would reduce the Geron stockholders’
ownership in BAC to 19.2%. BAC would also be committed to pay
to Geron royalties on the sale of products that are
commercialized in reliance upon Geron patents acquired by
BAC.”
Prior to release of the letter of
intent, an article earlier this week by Vickie Brower in The Scientist said,
intent, an article earlier this week by Vickie Brower in The Scientist said,
“The offer couldn’t come at a
better time for Geron, which in recent months has started to feel
pressure from its shareholders to boost its stock price and move
products through the pipeline. Since last November, when the company
announced its decision to shutter its hESC and regenerative medicine
business and funnel its resources into developing telomerase-related
treatments for cancer, the stock price has dropped more than 50
percent to $1.30 a share. Geron claimed the move was simply to save
money, but many took the decision—which effectively terminated a
clinical trial of an hESC treatment for spinal cord injury—as a
setback for the entire field."
News coverage of yesterday's
announcement was light. Here is a link to a piece by Ryan McBride on
Fierce Biotech.
Geron's stock price closed at $1.21
yesterday and rose to $1.24 in after hours trading. BioTime closed at
$2.97. No after hours trading was reported for BioTime.
yesterday and rose to $1.24 in after hours trading. BioTime closed at
$2.97. No after hours trading was reported for BioTime.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Geron, BioTime Deal Moves Forward with Letter of Intent
BioTime Will Have to Compete for California Cash for Geron's Dormant Clinical Trial
Posted: November 18, 2012 at 7:59 am
The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.
Kevin McCormack, senior director for
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
Responding to a question from the
California Stem Cell Report, McCormack said,
California Stem Cell Report, McCormack said,
“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”
McCormack later added that BioTime
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
The stem cell agency made its $25
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
The company has tried to sell the
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
News from clinical trial is expected to
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
Geron's stock traded at $1.24 at the
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on BioTime Will Have to Compete for California Cash for Geron's Dormant Clinical Trial